Letters NICE on hypertension

Authors’ reply to Harding and colleagues, Taylor, Cruickshank, and El Turabi and Payne

BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d6506 (Published 12 October 2011) Cite this as: BMJ 2011;343:d6506
  1. Bryan Williams, professor of medicine1,
  2. Taryn Krause, senior project manager, research fellow2,
  3. Kate Lovibond, senior health economist2,
  4. Mark Caulfield, professor of clinical pharmacology3,
  5. Terry McCormack, general practitioner4
  6. On behalf of the Guideline Development Group
  1. 1Department of Cardiovascular Sciences, University of Leicester and Leicester NIHR Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester LE2 7LX, UK
  2. 2National Clinical Guideline Centre Acute and Chronic Conditions, Royal College of Physicians, London NW1 4LE, UK
  3. 3William Harvey Research Institute, Barts and the London School of Medicine, and NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, London EC1M 6BQ, UK
  4. 4Whitby Group Practice, Spring Vale Medical Centre, Whitby YO21 1SD, UK
  1. bw17{at}le.ac.uk

We agree with Harding and colleagues that special consideration should be given to prescribing antihypertensive treatment to women of childbearing potential.1 The important guidance they cite is included in all of the guideline outputs from the National Institute for Health and Clinical Excellence (NICE).

In reply to Taylor,2 we considered all data on the prognostic value of ambulatory blood pressure monitoring (APBM) compared with clinic blood pressure and home blood pressure monitoring and found that as APBM best predicted clinical outcomes …

View Full Text

Sign in

Log in through your institution

Subscribe